#1 Clinical Trials Search in Europe

Cd1C+/Cd141+ Myeloid Dendritic Cells Isolated From Peripheral Blood Mononuclear Cells

This article explores an innovative clinical trial investigating the use of CD1C+/CD141+ Myeloid Dendritic Cells isolated from peripheral blood mononuclear cells in combination with other immunotherapy drugs for the treatment of recurrent glioblastoma. The study aims to evaluate the safety and effectiveness of this novel approach in patients who have undergone surgery for this aggressive brain cancer.

Table of Contents

What are CD1C+/CD141+ Myeloid Dendritic Cells?

CD1C+/CD141+ Myeloid Dendritic Cells, also known as BDCA-1+/BDCA-3+ myeloid dendritic cells, are a type of immune cell isolated from a patient’s own blood[1]. These cells are part of a new and innovative treatment approach called cell therapy. In this treatment, these specific dendritic cells are extracted from the patient’s blood, processed, and then used as a medication.

Medical Condition Treated

This treatment is being studied for patients with recurrent glioblastoma[1]. Glioblastoma is a type of aggressive brain cancer that often returns after initial treatment. When it comes back, it’s called recurrent glioblastoma.

How the Treatment Works

The treatment involves several steps:

  1. Collecting the patient’s blood cells through a process called leukapheresis
  2. Isolating and processing the specific CD1C+/CD141+ myeloid dendritic cells
  3. Injecting these processed cells directly into the brain tumor or the area where the tumor was removed
  4. Combining this cell therapy with other cancer treatments called nivolumab and ipilimumab

The goal is to stimulate the patient’s immune system to fight the cancer cells more effectively[1].

Clinical Trial Details

This treatment is currently being studied in a Phase I clinical trial. The main objectives of the trial are:

  • To assess the safety of injecting these dendritic cells along with nivolumab and ipilimumab
  • To evaluate how well this combination therapy works against the tumor

The trial is also looking at how long patients survive without their cancer getting worse (progression-free survival) and overall survival rates[1].

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key requirements include:

  • Being 18 years or older
  • Having a confirmed diagnosis of recurrent glioblastoma
  • Having completed previous standard treatments (surgery, radiation, and chemotherapy with temozolomide)
  • Having adequate organ function and overall health status
  • Not having certain autoimmune diseases or other cancers

There are additional specific medical criteria that doctors will evaluate to determine if a patient is eligible for the trial[1].

Potential Benefits and Risks

Potential benefits of this treatment may include:

  • A new option for treating recurrent glioblastoma, which can be difficult to treat
  • Possible improvement in survival time or quality of life
  • Contributing to the advancement of cancer research

However, as with any experimental treatment, there are also potential risks:

  • Side effects from the cell therapy or the other medications used
  • The possibility that the treatment may not be effective
  • Risks associated with the surgical procedures needed to deliver the treatment

It’s important for patients to discuss these potential benefits and risks thoroughly with their healthcare team before deciding to participate in the clinical trial[1].

Aspect Details
Study Type Phase I clinical trial
Condition Recurrent glioblastoma
Main Treatment Autologous CD1C+/CD141+ myeloid dendritic cells, nivolumab, and ipilimumab
Administration Routes Intratumoral, intracavitary, and intravenous
Primary Outcome Incidence of treatment-related severe adverse events
Secondary Outcomes Objective response rate (ORR), progression-free survival (PFS), overall survival (OS)
Key Eligibility Criteria Adults with recurrent glioblastoma, previous standard treatment, adequate organ function
Exclusion Criteria Active autoimmune disease, recent use of immunosuppressive medications, other severe medical conditions

FAQ

  • What is the main purpose of this clinical trial? The main purpose of this clinical trial is to assess the safety and anti-tumor activity of injecting autologous CD1C+/CD141+ myeloid dendritic cells along with nivolumab and ipilimumab in patients with recurrent glioblastoma who have undergone tumor resection or biopsy.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with a histopathological diagnosis of recurrent glioblastoma who have previously undergone surgery, radiation therapy, and temozolomide chemotherapy. They must have adequate organ function and meet specific criteria regarding their overall health status.
  • What are the main treatments being studied in this trial? The trial is studying the combination of autologous CD1C+/CD141+ myeloid dendritic cells, nivolumab, and ipilimumab. These treatments are administered through various routes, including intratumoral, intracavitary, and intravenous injections.
  • What are the primary outcomes being measured? The primary outcome being measured is the incidence of treatment-related severe adverse events for each dose level of ipilimumab. This helps determine the safety profile of the treatment combination.
  • How will the effectiveness of the treatment be evaluated? The effectiveness of the treatment will be evaluated through several secondary outcomes, including objective response rate (ORR) according to specific criteria, progression-free survival (PFS), and overall survival (OS). These measures will help assess the anti-tumor activity of the treatment combination.

Ongoing Clinical Trials on Cd1C+/Cd141+ Myeloid Dendritic Cells Isolated From Peripheral Blood Mononuclear Cells

  • Study on the Safety and Effectiveness of Nivolumab, Ipilimumab, and Myeloid Dendritic Cells for Patients with Recurrent Glioblastoma After Surgery

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Glioblastoma: A highly aggressive type of brain cancer that forms from glial cells (cells that support and protect nerve cells).
  • Myeloid Dendritic Cells: A type of immune cell that helps stimulate an immune response by presenting antigens to other immune cells.
  • Autologous: Derived from the same individual. In this context, it refers to using the patient's own cells for treatment.
  • Nivolumab: An immunotherapy drug that works by blocking a protein called PD-1, which helps activate the immune system to fight cancer cells.
  • Ipilimumab: Another immunotherapy drug that works by blocking a protein called CTLA-4, also helping to activate the immune system against cancer.
  • Intratumoral: Administered directly into the tumor.
  • Intracavitary: Administered into a cavity, in this case, likely the surgical cavity left after tumor removal.
  • Intravenous: Administered directly into a vein.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or getting worse.
  • Overall survival (OS): The length of time from the start of treatment that patients diagnosed with the disease are still alive.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-nivolumab-ipilimumab-and-myeloid-dendritic-cells-for-patients-with-recurrent-glioblastoma-after-surgery/